Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models
authors de Oliveira, JMPF; Pacheco, AR; Coutinho, L; Oliveira, H; Pinho, S; Almeida, L; Fernandes, E; Santos, C
nationality International
journal ARCHIVES OF TOXICOLOGY
author keywords Osteosarcoma; P53; Combination therapy; Fisetin; Etoposide; Cell cycle regulators; MG-63 cells; Saos-2 cells
keywords COLON-CANCER CELLS; CYCLE ARREST; FLAVONOID FISETIN; TOPOISOMERASE-II; APOPTOSIS; INHIBITION; P53; ACTIVATION; PROLIFERATION; POLYPHENOLS
abstract Osteosarcoma chemotherapy is often limited by chemoresistance, resulting in poor prognosis. Combined chemotherapy could, therefore, be used to prevent resistance to chemotherapeutics. Here, the effects of fisetin on osteosarcoma cells were investigated, as well as cytostatic potential in combination with the anti-cancer drug etoposide. For this, different osteosarcoma cell lines were treated with fisetin, with etoposide and with respective combinations. Fisetin was associated with decrease in colony formation in Saos-2 and in U2OS cells but not in MG-63 cells. Notwithstanding, upon evaluation of cellular growth by crystal violet assay, MG-63 and Saos-2 cells showed decreased cell proliferation at 40 and 20 A mu M fisetin, respectively. Depending on the relative concentrations, fisetin:etoposide combinations showed negative-to-positive interactions on the inhibition of cell proliferation. In addition, fisetin treatment up to 50 A mu M for 48 h resulted in G2-phase cell cycle arrest. Regardless of the combination, fisetin:etoposide increased % cells in G2-phase and decreased % cells in G1-phase. In addition, mixtures with more positive combined effects induced increased % cells in S-phase. Compared to etoposide treatment, these combinations resulted in decreased levels of cyclins B1 and E1, pointing to the role of these regulators in fisetin-induced cell cycle arrest. In conclusion, these results show that the combination of fisetin with etoposide has higher anti-proliferative effects in osteosarcoma associated with cell cycle arrest, allowing the use of lower doses of the chemotherapeutic agent, which has important implications for osteosarcoma treatment.
publisher SPRINGER HEIDELBERG
issn 0340-5761
year published 2018
volume 92
issue 3
beginning page 1205
ending page 1214
digital object identifier (doi) 10.1007/s00204-017-2146-z
web of science category Toxicology
subject category Toxicology
unique article identifier WOS:000428320800015
  ciceco authors
  impact metrics
journal analysis (jcr 2019):
journal impact factor 5.059
5 year journal impact factor 5.609
category normalized journal impact factor percentile 90.761
dimensions (citation analysis):
altmetrics (social interaction):



 


Sponsors

1suponsers_list_ciceco.jpg